HomeCompareBSX vs SYF

BSX vs SYF: Dividend Comparison 2026

BSX yields 3.18% · SYF yields 1.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SYF wins by $70.1K in total portfolio value
10 years
BSX
BSX
● Live price
3.18%
Share price
$62.93
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.32
Full BSX calculator →
SYF
SYF
● Live price
1.82%
Share price
$66.01
Annual div
$1.20
5Y div CAGR
49.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$90.4K
Annual income
$30,601.07
Full SYF calculator →

Portfolio growth — BSX vs SYF

📍 SYF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBSXSYF
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BSX + SYF cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BSX pays
SYF pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BSX
Annual income on $10K today (after 15% tax)
$270.14/yr
After 10yr DRIP, annual income (after tax)
$0.27/yr
SYF
Annual income on $10K today (after 15% tax)
$154.52/yr
After 10yr DRIP, annual income (after tax)
$26,010.91/yr
At 15% tax rate, SYF beats the other by $26,010.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BSX + SYF for your $10,000?

BSX: 50%SYF: 50%
100% SYF50/50100% BSX
Portfolio after 10yr
$55.3K
Annual income
$15,300.70/yr
Blended yield
27.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BSX right now

BSX
Analyst Ratings
2
Strong
38
Buy
3
Hold
Consensus: Buy
Price Target
$108.35
+72.2% upside vs current
Range: $94.00 — $130.00
Altman Z
3.9
Piotroski
7/9
SYF
Analyst Ratings
26
Buy
14
Hold
1
Strong
Consensus: Buy
Price Target
$90.08
+36.5% upside vs current
Range: $81.00 — $100.00
Altman Z
0.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BSX buys
6
SYF buys
0
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002026-02-10
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002026-01-30
Markwayne Mullin🏛 Senate$BSX▲ Buy$15,001 - $50,0002025-12-29
Markwayne Mullin🏛 Senate$BSX▲ Buy$15,001 - $50,0002025-12-29
Gilbert Cisneros🏢 House$BSX▼ Sell$1,001 - $15,0002025-12-24
John Boozman🏛 Senate$BSX▼ Sell$1,001 - $15,0002025-12-17
John Boozman🏛 Senate$BSX▼ Sell$1,001 - $15,0002025-12-17
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002025-11-18
Kevin Hern🏢 House$BSX▼ Sell$15,001 - $50,0002025-10-28
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002025-10-17
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBSXSYF
Forward yield3.18%1.82%
Annual dividend / share$2.00$1.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%49.4%
Portfolio after 10y$20.2K$90.4K
Annual income after 10y$0.32$30,601.07
Total dividends collected$321.00$64.6K
Payment frequencyquarterlyquarterly
SectorHealthcareFinancials
Analyst consensusBuyBuy
Analyst price target$108.35$90.08

Year-by-year: BSX vs SYF ($10,000, DRIP)

YearBSX PortfolioBSX Income/yrSYF PortfolioSYF Income/yrGap
1← crossover$10,859$158.91$10,972$271.60$113.00SYF
2$11,700$80.63$12,156$416.06$456.00SYF
3$12,559$40.60$13,650$643.63$1.1KSYF
4$13,459$20.36$15,615$1,009.16$2.2KSYF
5$14,411$10.20$18,320$1,611.86$3.9KSYF
6$15,425$5.10$22,243$2,640.44$6.8KSYF
7$16,507$2.55$28,276$4,476.19$11.8KSYF
8$17,664$1.28$38,200$7,945.19$20.5KSYF
9$18,901$0.64$55,862$14,987.29$37.0KSYF
10$20,225$0.32$90,373$30,601.07$70.1KSYF

BSX vs SYF: Complete Analysis 2026

BSXHealthcare

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Full BSX Calculator →

SYFFinancials

Synchrony Financial, together with its subsidiaries, operates as a consumer financial services company in the United States. It provides credit products, such as credit cards, commercial credit products, and consumer installment loans. The company also offers private label credit cards, dual cards, co-brand and general purpose credit cards, short- and long-term installment loans, and consumer banking products; and deposit products, including certificates of deposit, individual retirement accounts, money market accounts, and savings accounts to retail and commercial customers, as well as accepts deposits through third-party securities brokerage firms. In addition, it provides debt cancellation products to its credit card customers through online, mobile, and direct mail; healthcare payments and financing solutions under the CareCredit, Pets Best, and Walgreens brands; payments and financing solutions in the apparel, specialty retail, outdoor, music, and luxury industries; and point-of-sale consumer financing for audiology products and dental services. The company offers its credit products through programs established with a group of national and regional retailers, local merchants, manufacturers, buying groups, industry associations, and healthcare service providers; and deposit products through various channels, such as digital and print. It serves digital, health and wellness, retail, home, auto, powersports, jewelry, pets, and other industries. Synchrony Financial was founded in 1932 and is headquartered in Stamford, Connecticut.

Full SYF Calculator →
📬

Get this BSX vs SYF comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BSX vs SCHDBSX vs JEPIBSX vs OBSX vs KOBSX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.